Table 2.
Number of classes of oral antidiabetic medications prescribed in the GLP-1 RA populations
| Variable | All GLP-1 RA (n = 932) | Dulaglutide (n = 612) | Liraglutide (n = 271) | |||
|---|---|---|---|---|---|---|
| 6 months pre-index | 6 months post-index | 6 months pre-index | 6 months post-index | 6 months pre-index | 6 months post-index | |
| Oral antidiabetic medication classes, n (%) | ||||||
| 0 | 56 (6.0) | 137 (14.7) | 31 (5.1) | 76 (12.4) | 22 (8.1) | 54 (19.9) |
| 1 | 174 (18.7) | 308 (33.0) | 89 (14.5) | 192 (31.4) | 68 (25.1) | 96 (35.4) |
| 2 | 251 (26.9) | 312 (33.5) | 157 (25.7) | 211 (34.5) | 77 (28.4) | 86 (31.7) |
| 3 | 266 (28.5) | 143 (15.3) | 183 (29.9) | 107 (17.5) | 74 (27.3) | 29 (10.7) |
| ≥ 4 | 185 (19.8) | 32 (3.4) | 152 (24.8) | 26 (4.2) | 30 (11.1) | 6 (2.2) |
GLP-1 RA glucagon-like peptide-1 receptor agonist